Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Take heart, it’s all good news

31.03.2005


New evidence uncovered by researchers in Tayside and Bristol has shown wider benefits of cholesterol lowering drugs for large sections of the public, including women and the elderly.

Researchers have told us for years that cholesterol lowering drugs that lower blood fat levels provide large benefits to those who participated in clinical trails. However, the effects of these drugs were only really applicable to the sorts of carefully selected patients who actually participated in those trials.

The new evidence now available from a combined Tayside and Bristol research project, published this week in the British Medical Journal, shows that these drugs provide benefits of at least an equal level of benefit to patients groups who were excluded from the clinical trial - the old, the very old, women and those who are unfortunate enough to suffer from a number of other pre-existing diseases. This is really good news for those patients because it has often been found that when taken in general use rather than in clinical trials, medicines do not seem to work as well. This can be because the people in the trials have been selected to be those that will benefit most or those that will have the fewest side effects.



Professor Tom MacDonald, of the University of Dundee, the lead author of the research said “The results of this study are very important as we know now that all patients get similar benefits to those who were in the original studies. It is also good news for the research technique of studying routinely collected data (in an anonymous way of course) of many NHS patients and importantly using quality NHS data as well as being able to bring together data from a range of NHS sources. Such research has important implications in ensuring a good risk/benefit ratio for all medicines.”

The study looked at the data of nearly 5000 patients who were discharged from hospital following a heart attack over an 8 year period. The researchers checked to see the level of cardiovascular outcomes or deaths occurring in these patients and whether they had been treated with statin (the name for a particular type of drug class that lowers cholesterol). Those treated with statins had lower rates of cardiovascular outcomes and death compared to those not treated and the level of benefit were similar across all patient groups. Additionally this research study included a far greater proportion of women and showed they also had good results.

This research is part of an on-going series of projects being undertaken by university researchers in conjunction with the NHS in Tayside that uses advanced methods to develop anonymous clinical information. This ensures that the researchers can make the maximum use of such information whilst ensuring confidentiality. Such research helps to ensure that the treatments available on the NHS have the right balance of benefit and risk.

Roddy Isles | alfa
Further information:
http://www.dundee.ac.uk/pressreleases/prmar05/heart.html

More articles from Health and Medicine:

nachricht Speed data for the brain’s navigation system
06.12.2016 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Predicting unpredictability: Information theory offers new way to read ice cores

07.12.2016 | Earth Sciences

Sea ice hit record lows in November

07.12.2016 | Earth Sciences

New material could lead to erasable and rewriteable optical chips

07.12.2016 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>